Preclinical News and Research

RSS

Comprehensive insight into current neural stem cell research and therapies

A new article published by Cell Press in the May 26 issue of the journal Neuron provides comprehensive insight into the current status of neural stem cell research and the sometimes labyrinthine pathways leading to stem cell-based therapies.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced today that new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.

25 May 2011

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.

25 May 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Practical solutions for translational science from Randox Laboratories

The sole purpose of translational science is to transfer scientific discoveries made in ‘basic research’ to clinical reality, to improve the health of individuals and reduce suffering.

From Randox Laboratories Ltd. 23 May 2011

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Sangamo BioSciences, Inc. announced today that data from clinical, preclinical and research-stage programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in twenty presentations given by Sangamo scientists and collaborators at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

Oxford BioMedica, a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin for the treatment of Parkinson's disease were presented at the American Society of Gene & Cell Therapy 14th Annual Meeting held in Seattle, USA by Professor Stephane Palfi, Principal Investigator at the Henri Mondor Hospital in Paris, on Saturday 21 May 2011.

23 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its first quarter ended March 31, 2011.

19 May 2011

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research.

19 May 2011

Humanized BLT mice help prevent HIV/AIDS transmission

The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission.

19 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Preclinical News and Research

Comprehensive insight into current neural stem cell research and therapies

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

CRT, Cancer Research UK and Centella partner to launch clinical development of CEN-209

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Practical solutions for translational science from Randox Laboratories

Sangamo announces presentations of ZFP Therapeutics data at ASGCT 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

New data from ProSavin Phase I/II trial in Parkinson's presented at ASGCT annual meeting

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

Humanized BLT mice help prevent HIV/AIDS transmission

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics